Generic Medicine Info
Indications and Dosage
Prophylaxis of acute graft rejection in renal transplantation
Adult: In combination w/ ciclosporin and corticosteroids: 20 mg by bolus inj or by infusion over 20-30 min 2 hr prior to transplantation, followed by 20 mg after 4 days, withhold 2nd dose if severe hypersensitivity or graft loss occurs.
Child: In combination w/ ciclosporin and corticosteroids: <35 kg: 10 mg by bolus inj or by infusion over 20-30 min 2 hr before surgery, repeated once 4 days later; ≥35 kg: Same as adult dose. Withhold 2nd dose if graft loss or severe hypersensitivity reaction occurs.
Reconstitute 10 mg and 20 mg vial w/ 2.5 mL and 5 mL sterile water for inj, respectively. To prepare the soln for infusion, further dilute w/ 25 mL (10 mg) or 50mL (20 mg) NaCl 0.9% soln or dextrose 5% in water.
Special Precautions
Re-exposure to a subsequent course of therapy in patient who has previously received basiliximab. Childn. Pregnancy and lactation.
Adverse Reactions
Anaphylaxis and other severe, acute hypersensitivity reactions (e.g. hypotension, tachycardia, cardiac failure, dyspnoea, wheezing, bronchospasm, pulmonary oedema, resp failure, urticaria, rash, pruritus, sneezing), lymphoproliferative disorders, opportunistic infections; constipation, nausea, diarrhoea, abdominal pain, vomiting, dyspepsia, enlarged abdomen, esophagitis, flatulence, gastroenteritis, GI hemorrhage, gum hyperplasia, melaena, moniliasis, ulcerative stomatitis; pain, peripheral oedema, fever, accidental trauma, asthenia, fatigue, malaise, rigors, sepsis; hyperkalaemia, hypokalaemia, hyperuricaemia, hypophosphataemia, hypercholesterolaemia, acidosis, dehydration, DM, fluid overload, hypercalcaemia, hyperlipaemia, hypertriglyceridaemia, hypocalcaemia, hypoglycaemia, hypomagnesaemia, hypoproteinaemia, wt gain; headache, tremor, dizziness, neuropathy, paraesthesia, hypoaesthesia; UTI, albuminuria, dysuria, haematuria, oliguria, abnormal renal function, renal tubular necrosis, urinary retention, ureteral disorder; HTN; acne; insomnia; anaemia, polycythaemia; haematoma, haemorrhage, purpura, thrombocytopenia, thrombosis; arrhythmia, atrial fibrillation; arthralgia, arthropathy, back pain, bone fracture, cramps, hernia, myalgia, leg pain; impotence; cataract, conjunctivitis, abnormal vision; hypertrichosis, skin ulceration.
Monitoring Parameters
Monitor signs and symptoms of acute rejection, infection and hypersensitivity; cardiorespiratory and renal function.
Drug Interactions
May diminish response to inactivated vaccines. May enhance the adverse/toxic effect of live vaccines, avoid concomitant admin.
Mechanism of Action: Basiliximab is a chimeric murine/human monoclonal antibody. It blocks the α-chain (CD25 antigen) of the interleukin-2 receptor complex on the surface of activated T-lymphocytes.
Duration: 36 days ± 14 days.
Distribution: Volume of distribution: 8.6 ± 4.1 L.
Excretion: Terminal half-life: 7 days.
Store between 2-8°C. Reconstituted soln: 2-8°C for 24 hr or 4 hr at room temp.
MIMS Class
ATC Classification
L04AC02 - basiliximab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Anon. Basiliximab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 08/08/2016.

Buckingham R (ed). Basiliximab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 08/08/2016.

Joint Formulary Committee. Basiliximab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 08/08/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Basiliximab. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 08/08/2016.

Simulect inj, powder, for solution (Novartis Pharmaceuticals Corporation). DailyMed. Source: U.S. National Library of Medicine. Accessed 08/08/2016.

Wickersham RM. Basiliximab. Facts and Comparisons [online]. St. Louis, MO. Wolters Kluwer Clinical Drug Information, Inc. Accessed 30/08/2016.

Disclaimer: This information is independently developed by MIMS based on Basiliximab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in